IL135957A0 - Diagnostics and therapeutics for chronic obstructive airway disease - Google Patents

Diagnostics and therapeutics for chronic obstructive airway disease

Info

Publication number
IL135957A0
IL135957A0 IL13595798A IL13595798A IL135957A0 IL 135957 A0 IL135957 A0 IL 135957A0 IL 13595798 A IL13595798 A IL 13595798A IL 13595798 A IL13595798 A IL 13595798A IL 135957 A0 IL135957 A0 IL 135957A0
Authority
IL
Israel
Prior art keywords
chronic obstructive
therapeutics
diagnostics
obstructive airway
airway disease
Prior art date
Application number
IL13595798A
Other languages
English (en)
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9723553.5A external-priority patent/GB9723553D0/en
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of IL135957A0 publication Critical patent/IL135957A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13595798A 1997-11-07 1998-11-09 Diagnostics and therapeutics for chronic obstructive airway disease IL135957A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9723553.5A GB9723553D0 (en) 1997-11-07 1997-11-07 Prediction of the risk of chronic obstructive airway disease
US09/005,923 US6140047A (en) 1997-11-07 1998-01-12 Method and kit for predicting susceptibility to asthma
PCT/US1998/023721 WO1999024615A2 (fr) 1997-11-07 1998-11-09 Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires

Publications (1)

Publication Number Publication Date
IL135957A0 true IL135957A0 (en) 2001-05-20

Family

ID=26312564

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13595798A IL135957A0 (en) 1997-11-07 1998-11-09 Diagnostics and therapeutics for chronic obstructive airway disease

Country Status (13)

Country Link
EP (1) EP1029079B1 (fr)
JP (1) JP2001522586A (fr)
AT (1) ATE383438T1 (fr)
AU (1) AU760856B2 (fr)
BR (1) BR9813950A (fr)
CA (1) CA2308570A1 (fr)
ES (1) ES2297900T3 (fr)
HU (1) HUP0301197A2 (fr)
IL (1) IL135957A0 (fr)
NO (1) NO20002176L (fr)
PL (1) PL340624A1 (fr)
TR (1) TR200001263T2 (fr)
WO (1) WO1999024615A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
CA2367294A1 (fr) * 1999-04-02 2000-10-12 Interleukin Genetics, Inc. Prediction des risques de pathologie interstitielle pulmonaire
AU7706000A (en) * 1999-09-22 2001-04-24 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin-1 beta gene
WO2002000933A2 (fr) * 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Essais de recherche systematique de modulateurs de la reaction inflammatoire ou immunitaire
WO2005019259A2 (fr) * 2003-08-25 2005-03-03 Compugen Ltd. Variants de l'antagoniste du recepteur d'interleukine-1: compositions et utilisations correspondantes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (fr) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease

Also Published As

Publication number Publication date
JP2001522586A (ja) 2001-11-20
TR200001263T2 (tr) 2000-12-21
WO1999024615A3 (fr) 1999-09-16
CA2308570A1 (fr) 1999-05-20
PL340624A1 (en) 2001-02-12
ES2297900T3 (es) 2008-05-01
AU1386399A (en) 1999-05-31
HUP0301197A2 (hu) 2003-07-28
NO20002176L (no) 2000-07-05
BR9813950A (pt) 2000-09-26
EP1029079A2 (fr) 2000-08-23
ATE383438T1 (de) 2008-01-15
AU760856B2 (en) 2003-05-22
WO1999024615A2 (fr) 1999-05-20
NO20002176D0 (no) 2000-04-27
EP1029079B1 (fr) 2008-01-09

Similar Documents

Publication Publication Date Title
IL142438A0 (en) Diagnostic and therapeutics for sepsis
AU5212199A (en) Methods and kits for diagnosing and determination of the predisposition of diseases
WO1996012189A3 (fr) PROCEDES DE DEPISTAGE DE LA RECTOCOLITE HEMORRAGIQUE ET DE LA MALADIE DE CROHN PAR DETECTION DE L'AUTOANTICORPS VH3-15 ET DE pANCA
EP0842042A4 (fr) Procedes ameliores de fabrication de particules a sensibilite magnetique
IL146631A0 (en) Diagnostics and therapeutics for cardiovascular disorders
AU4157696A (en) Quantitative method for early detection of mutant alleles and diagnostic kits for carrying out the method
FR2718428B1 (fr) Procédé et installation de production de monoxyde de carbone.
FR2750188B1 (fr) Dispositif et procede de determination de l'epaisseur d'une garniture de frein
WO2001000880A3 (fr) Diagnostic et traitement des maladies associees a l'haplotype inflammatoire il-1
ES2166822T3 (es) Procedimientos de seleccion de la enfermedad de crohn usando alelos de microsatelites de tnf.
IL135957A0 (en) Diagnostics and therapeutics for chronic obstructive airway disease
WO2002002000A3 (fr) Methodes de criblage de la maladie d'alzheimer
DE69613172T2 (de) Verstärkungsbänder für Reissverschluss
FR2656972B1 (fr) Procede de preparation d'un diaphragme entierement carbone pour equipement acoustique.
FR2722001B1 (fr) Procede de caracterisation non destructif de l'etat de surface d'une piece
EP1111049A4 (fr) Nouvelle proteine de recepteur et procede servant a diagnostiquer des maladies inflammatoires au moyen de cette proteine
DE69634943D1 (de) Verbesserte Festpartikeldispersionen für Aufzeichnungselemente
FR2770218B1 (fr) Procede de silylation d'hydrates de carbone
DE69016316T2 (de) Toner für Elektrophotographie und Verfahren zu dessen Herstellung.
ATE408708T1 (de) Mutationen in verbindung mit eisenerkrankungen
ATE275268T1 (de) Verfahren zur diagnose von sjögren-syndrom
WO2000071753A3 (fr) Methodes diagnostiques et therapeutiques contre la restenose
FR2758186B1 (fr) Procede non destructif pour estimer le vieillissement d'une piece en materiau composite
DE69534178D1 (en) S?ugetier thymokingene
WO2003104812A3 (fr) Dosage de diagnostic de la maladie d'alzheimer reposant sur la determination du taux de ha dollar g(b)42:ha dollar g(b)40